Traditional Chinese Medicines Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao (Glycyrrhiza uralensis Fisch) Activate Pregnane X Receptor and Increase Warfarin Clearance in Rats
- Ying Mu,
- Jinnan Zhang,
- Shimin Zhang,
- Hong-Hao Zhou,
- David Toma,
- Songrong Ren,
- Leaf Huang,
- Maria Yaramus,
- Andrew Baum,
- Raman Venkataramanan and
- Wen Xie
- Center for Pharmacogenetics (Y.M., D.T., S.R., L.H., W.X.) and Departments of Pharmaceutical Sciences (Y.M., S.Z., D.T., S.R., L.H., R.V., W.X.) and Pharmacy and Therapeutics (M.Y.), University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania; Department of Chem-Pharmacology, Capital University of Medical Sciences in Beijing China, Beijing, China (J.Z.); Institute of Clinical Pharmacology, Central South University, Changsha, Hunan, China (H.-H.Z.); and Integrative Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania (A.B.)
- Address correspondence to:
Dr. Wen Xie, Center for Pharmacogenetics, 633 Salk Hall, University of Pittsburgh, Pittsburgh, PA 15261. E-mail: wex6{at}pitt.edu
Abstract
The traditional Chinese medicines (TCMs) are essential components of alternative medicines. Many TCMs are known to alter the expression of hepatic drug-metabolizing enzymes and transporters. The molecular mechanism by which TCMs and/or their constituents regulate enzyme and transporter expression, however, has remained largely unknown. In this report, we show that two TCMs, Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao (Glycyrrhiza uralensis Fisch), and their selected constituents activate the xenobiotic orphan nuclear receptor pregnane X receptor (PXR). Treatment with TCM extracts and the Schisandrol and Schisandrin constituents of Wu Wei Zi induced the expression of drug-metabolizing enzymes and transporters in reporter gene assays and in primary hepatocyte cultures. The affected enzymes and transporters include CYP3A and 2C isozymes and the multidrug resistance-associated protein 2. In transient transfection and reporter gene assays, the Schisandrin constituents of Wu Wei Zi had an estimated EC50 of 2 and 1.25 μM on hPXR and mPXR, respectively. Interestingly, mutations that were intended to alter the pore of the ligand-binding cavity of PXR had species-specific effects on the activities of the individual Schisandrols and Schisandrins. In rats, the administration of Wu Wei Zi and Gan Cao increased the metabolism of the coadministered warfarin, reinforcing concerns involving the safe use of herbal medicines and other nutraceuticals to avoid PXR-mediated drug-drug interactions. Meanwhile, the activation of PXR and induction of detoxifying enzymes provide a molecular mechanism for the hepatoprotective effects of certain TCMs.
Footnotes
-
This work was supported in part by National Institutes of Health Grants ES012479 and CA107011 (to W.X.) and by a Traditional Chinese Medicine pilot grant from the University of Pittsburgh Cancer Institute. Y.M. is supported by National Institutes of Health International Postdoctoral Fellowship AT002029. J.Z. is supported by the Beijing Municipal Department of Education (Research Grant KM20041025007). Normal human hepatocytes were obtained through the Liver Tissue Procurement and Distribution System (Pittsburgh, PA), which was funded by National Institutes of Health Contract N01-DK-9-2310.
-
doi:10.1124/jpet.105.094342.
-
ABBREVIATIONS: TCM, traditional Chinese medicine; PXR, pregnane X receptor; RIF, rifampicin; PCN, pregnanenolone-16α-carbonitrile; RT, room temperature; HPLC, high-performance liquid chromatography; MRP2, multidrug resistance-associated protein 2; LBD, ligand-binding domain; rPXR, rat PXR; UAS, upstream activating sequence; tk, thymidine kinase; P450, cytochrome P450.
-
- Received August 17, 2005.
- Accepted October 24, 2005.
- The American Society for Pharmacology and Experimental Therapeutics



